Literature DB >> 7235733

Inhibition of PMN leukocytes chemotaxis by thalidomide.

M Faure, J Thivolet, M Gaucherand.   

Abstract

The effects of thalidomide on chemotaxis of normal human peripheral blood PMN leukocytes have been studied in vitro. The chemotaxis factor was generated by interacting normal human serum with bovine gamma globulin-antibovine-gamma globulin immune complexes. At concentrations of 1, 10, and 100 microgram/ml, thalidomide failed to inhibit the chemotactic factor. At the same concentrations, erythromycin caused a marked inhibition of chemotaxis. Pre-incubation of PMNs with thalidomide or erythromycin caused a marked, dose-independent inhibition of chemotaxis. Random mobility did not appear to be affected. Inhibition of PMN chemotactic ability by thalidomide may account for its ability to improve inflammatory dermatoses, such as aphthosis.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7235733     DOI: 10.1007/bf00406421

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN: 0340-3696            Impact factor:   3.017


  4 in total

Review 1.  Physiology of chemotaxis and random motility.

Authors:  H U Keller; M W Hess; H Cottier
Journal:  Semin Hematol       Date:  1975-01       Impact factor: 3.851

2.  Thalidomide in the treatment of recurrent, necrotic, and giant mucocutaneous aphthae and aphthosis.

Authors:  J M Mascaro; M Lecha; H Torras
Journal:  Arch Dermatol       Date:  1979-05

3.  Chemotaxis for polymorphonuclear leucocytes induced by soluble antigen- antibody complexes.

Authors:  J Leung-Tack; J Maillard; G A Voisin
Journal:  Immunology       Date:  1977-12       Impact factor: 7.397

4.  The effect of antimicrobial agents on leukocyte chemotaxis.

Authors:  N B Esterly; N L Furey; L E Flanagan
Journal:  J Invest Dermatol       Date:  1978-01       Impact factor: 8.551

  4 in total
  7 in total

1.  Effects of thalidomide on the generation of oxygen intermediates by zymosan-stimulated normal polymorphonuclear leukocytes.

Authors:  Y Miyachi; M Ozaki; K Uchida; Y Niwa
Journal:  Arch Dermatol Res       Date:  1982       Impact factor: 3.017

2.  Synergy between RU 28965 (roxithromycin) and human neutrophils for bactericidal activity in vitro.

Authors:  M T Labro; N Amit; C Babin-Chevaye; J Hakim
Journal:  Antimicrob Agents Chemother       Date:  1986-07       Impact factor: 5.191

3.  Treatment of pyoderma gangrenosum with infliximab in Crohn's disease.

Authors:  Mark S Sapienza; Sidney Cohen; Anthony J Dimarino
Journal:  Dig Dis Sci       Date:  2004-09       Impact factor: 3.199

Review 4.  Thalidomide: rationale for renewed use in immunological disorders.

Authors:  U Schuler; G Ehninger
Journal:  Drug Saf       Date:  1995-06       Impact factor: 5.606

5.  Integrated pathways for neutrophil recruitment and inflammation in leprosy.

Authors:  Delphine J Lee; Huiying Li; Maria T Ochoa; Motoyuki Tanaka; Ryan J Carbone; Robert Damoiseaux; Anne Burdick; Euzenir N Sarno; Thomas H Rea; Robert L Modlin
Journal:  J Infect Dis       Date:  2010-02-15       Impact factor: 5.226

6.  Thalidomide: an emerging drug in oral mucosal lesions.

Authors:  K Mubeen; M Ahmed Siddiq; V R Jigna
Journal:  Clin J Gastroenterol       Date:  2009-06-02

Review 7.  Thalomid (Thalidomide) capsules: a review of the first 18 months of spontaneous postmarketing adverse event surveillance, including off-label prescribing.

Authors:  T E Clark; N Edom; J Larson; L J Lindsey
Journal:  Drug Saf       Date:  2001       Impact factor: 5.228

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.